about
Progress towards the integration of pharmacogenomics in practiceEffects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients.In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in ratsPrevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.The pharmacoepigenetics of drug metabolism and transport in breast cancer: review of the literature and in silico analysis.Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis.Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.The impact of pharmacokinetic gene profiles across human cancers.Interactions between Alcohol Consumption and Adjuvant Hormone Therapy in Relation to Breast Cancer-Free Survival.Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
P2860
Q28652270-92005CAA-2F50-418E-9C6A-7A154DD2BB33Q33589336-908D7955-61FD-4936-BFD3-E61376755594Q36243663-5F6FFF39-8774-446D-B0EE-72DBB46AFF6AQ36245924-A2A86A7B-06DA-48C8-8AA5-8418977516A2Q37170578-B8310690-91FA-4E1E-AE8C-30EDFD440EA5Q38604479-F520BDCC-685C-46B0-BA4D-DC1E14006E42Q38726658-7EA860F5-6CEC-4608-8C6A-7A43D27B17E8Q38937221-BD6D24F3-5768-473A-A053-7313E5B818F3Q39864884-B9E664B9-F56A-4B00-B303-E488931E8668Q40639052-47216A4B-1879-4B5A-B83B-AA343F778219Q45987663-5BF39C55-769C-4937-8266-EA3E00BFB86CQ47099651-49630E6C-4063-4446-B87A-AF524F4E9D64Q49554838-9CE69835-3CEA-4757-8BC2-49673887E795Q55294975-E69673AA-C031-4939-9729-6F3DF491C593Q55357811-51D4755A-816F-42F0-8CC4-88015AB0B75CQ58767256-5B9C1573-8F00-40D0-9F5B-57244B91D2D2
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
PharmGKB summary: tamoxifen pathway, pharmacokinetics
@ast
PharmGKB summary: tamoxifen pathway, pharmacokinetics
@en
type
label
PharmGKB summary: tamoxifen pathway, pharmacokinetics
@ast
PharmGKB summary: tamoxifen pathway, pharmacokinetics
@en
prefLabel
PharmGKB summary: tamoxifen pathway, pharmacokinetics
@ast
PharmGKB summary: tamoxifen pathway, pharmacokinetics
@en
P2093
P2860
P50
P1476
PharmGKB summary: tamoxifen pathway, pharmacokinetics
@en
P2093
Caroline F Thorn
Daniel J Klein
Teri E Klein
P2860
P304
P356
10.1097/FPC.0B013E3283656BC1
P577
2013-11-01T00:00:00Z